-

Vetoquinol: 2025 Calendar of Financial Communication

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) published its calendar of financial communication for 2025.

January 30, 2025

2024 Annual Sales (after market)

March 20, 2025

2024 Annual results (confcall after market)

April 24, 2025

2025 First quarter sales (after market)

May 22, 2025

Annual shareholders’ meeting

June 6, 2025

Dividend payment

September 11, 2025

2025 First semester results (confcall after market)

October 28, 2025

2025 Third quarter sales (after market)

Next update: Annual Sales 2024, January 30th, 2025 after market close

ABOUT VETOQUINOL

Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.

Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and pets (dogs, cats).

Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. At June 30, 2024, Vetoquinol employed 2,519 people.

Vetoquinol has been listed on Euronext Paris since 2006 (mnemonic code: VETO).

The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

Vetoquinol

BOURSE:VETO
Release Versions
EnglishFrench

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

More News From Vetoquinol

Vetoquinol: Sales at End September 2025

LURE, France--(BUSINESS WIRE)--Regulatory News: At the end of September 2025, Vetoquinol's (Paris:VETO) sales amounted to €384.2 million, down 3.5% on a reported basis and down 1.3% at constant exchange rates. Over this period, the Group recorded net negative currency impacts of €8.9 million in the Americas and Asia-Pacific/Rest of the World regions and an impact of - €7.7 million from the simplification of complementary ranges, mainly in Europe. Net of these two items, sales for the first nine...

Vetoquinol: 2025 Half Year Results

LURE, France--(BUSINESS WIRE)--Regulatory News: The Board of Directors of Vetoquinol SA (Paris:VETO), meeting on September 9, 2025, approved the financial statements for the first half of the 2025 financial year. The limited review report on the financial statements as of June 30, 2025, was issued by the Statutory Auditors. Vetoquinol's sales amounted to €258 million for the first six months of fiscal year 2025. Sales of Essentials products amounted to €165 million, up 4.2% at constant exchange...

Vetoquinol: Availability of the 2024 Universal Registration Document

LURE, France--(BUSINESS WIRE)--Regulatory News: On 24 April 2025, Vetoquinol (Paris:VETO) filed its 2024 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). The 2024 Universal Registration Document in ESEF and PDF formats (reproduction of the official version of the Universal Registration Document in ESEF format) is available to the public under the conditions provided by applicable regulations and may be consulted on the “...
Back to Newsroom